AOD-9604 Peptide

A drug candidate that failed, then got a new job title.

AOD-9604 is a 16-amino-acid peptide, sequence YLRIVQCRSVEGSCGF, described by the FDA as a synthetic fragment of human growth hormone spanning residues 177 to 191 with an additional tyrosine at the N terminus and a disulphide bond between the cysteines at positions 7 and 14, free base formula C78H123N23O23S2, molar mass 1815.09, CAS 221231-10-3. Six randomised double-blind placebo-controlled human trials were run, the pivotal obesity trial found no significant weight loss against placebo, and the FDA restated that in writing in its 2024 review.

Growth hormone is a big molecule, 191 residues, doing a lot of different jobs at once.

The idea here was reasonable enough. If the different jobs live in different regions, clip off the region you want and leave the rest behind.

Metabolic Pharmaceuticals, an Australian company, was built substantially around this one asset. The programme ran through the 2000s.

Then the OPTIONS study read out, and the programme ended.

That is not a controversial reading. That is what happened.

A sixteen-residue tail clipped off a much larger hormone, with a bit added back on.

Alright, here's the honest problem with explaining the mechanism.

The clean version goes: clip the fragment, keep one activity, drop the rest. Tidy.

Attractive. Easy to put on a label.

So anything you read describing a confident mechanism of action for this compound is describing a hypothesis that was tested and did not carry, written as though the testing never happened.

Worth knowing where the rest of the claims come from too. A lot of what circulates about the bare 176-191 fragment is actually borrowed from papers about this molecule, and a lot of what circulates about this molecule is borrowed from the era before the readout.

Here's the honest part. We stock it, we test it, and we are not going to pretend the file says something it doesn't.

A failed endpoint is data. It is just data nobody wants to put in a product description.

The interesting part isn't the pharmacology. It's the paperwork.

The scientifically interesting thing about AOD-9604 is not the pharmacology. It's what happened after the pharmacology stopped cooperating.

The programme ended when the pivotal study read out.

There is a 2014 paper, by company-affiliated authors, titled as a novel nutraceutical ingredient, which asserts self-affirmed generally recognised as safe status for use in foods, drinks and supplements.

Read that sentence twice. Self-affirmed means the affirming was done by the party that benefits from it. It is a real regulatory pathway and it is also not the same thing as a regulator agreeing.

So the honest summary: a drug candidate whose trial did not deliver, given a second commercial life through a different classification, with the safety position partly self-declared.

None of that makes it uninteresting. It makes it a case study, and we would rather hand you the case study than a slogan.

Same day out of British Columbia. Our building, our cold packs, our people, and nothing sitting in a customs queue while you refresh a tracking page.

Then into the fridge. Keep it cold and keep it dark. Sealed and freeze-dried it handles a rough trip without ice. Once it lands, fridge.

We are not going to claim it works. This compound is bought on a reputation its own pivotal trial did not support. FDA has published that conclusion. We stock it because there is demand for it, and we would rather tell you what the file says than sell you a story it does not support.